Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Bath & Body Works Names Daniel Heaf CEO

Bath & Body Works Reports Strong First Quarter 2025 Results

Bath & Body Works, Inc. has announced the appointment of Daniel Heaf as its new Chief Executive Officer, effective immediately. The company also pre-announced its first quarter 2025 results, revealing a net sales figure of $1.4 billion and earnings per diluted share of $0.49. This meets the high end of the sales guidance and exceeds the EPS guidance.

The first quarter of 2025 saw a 3% increase in net sales compared to the prior year period. Earnings per diluted share for the same period were $0.49, up from $0.38 in the previous year. These results have led the company to maintain its full-year 2025 outlook, projecting a 1% to 3% growth in net sales and $3.25 to $3.60 earnings per diluted share.

Daniel Heaf, the newly appointed CEO, brings with him a successful track record from his previous roles at global consumer and retail companies. He aims to lead Bath & Body Works into its next phase of growth, leveraging the company's strong foundation and large customer base.

Gina Boswell has stepped down from her role as CEO and as a member of the Bath & Body Works board, effective immediately. The board expressed gratitude for her contributions, particularly in stabilizing the business and returning it to profitable revenue growth during the post-COVID normalization period.

The company will conduct its first quarter earnings call on Thursday, May 29, 2025, where investors can expect to hear from the board chair, the new CEO, and the chief financial officer.

Following these announcements, the company's shares moved 0.06%, and are now trading at a price of $33.78. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS